Shares in drugmakers AstraZeneca and Shire both fell more than 5 percent after the U.S. Treasury took steps to curb “inversion” deals.
Shares in drugmakers AstraZeneca and Shire both fell more than 5 percent after the U.S. Treasury took steps to curb “inversion” deals.